Shire Reports Revenue Growth – Zacks.com
|
Shire Reports Revenue Growth
Zacks.com The decrease royalty revenue was primarily due to 57% fall in 3TC and Zeffix royalties (.3 million), partially offset by 27% and 56% rise in Adderall XR (.9 million) and Fosrenol (.9 million) royalties respectively. … and more » |
